Article
Deep learning radiopathomics predicts targeted therapy sensitivity in EGFR-mutant lung adenocarcinoma.
Journal of translational medicine - 29 Apr 2025
Yang Taotao, Wang Xianqi, Jin Yuan, Yao Xiaohong, Sun Zhiyuan, Chen Pinzhen, Zhou Suyi, Zhu Wentao, Chen Wei
Abstract excerpt
BACKGROUND: Ttyrosine kinase inhibitors (TKIs) represent the standard first-line treatment for patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. However, not all patients with EGFR mutations respond to TKIs. This study aims to develop a deep learning radiological-pathological-clinical (DLRPC) model that integrates computed tomography (CT) images, hematoxylin and eosin (H&E)-stained...
Read the complete abstract on PubMedTopics
- Humans
- Adenocarcinoma of Lung
- ErbB Receptors
- Deep Learning
- Mutation
- Male
